Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biosensors International | OTHER |
| Boston Scientific Corporation | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare early vessel healing after implantation of SYNERGY drug eluting stent (DES) or BioMatrix NeoFlex DES at one and three months in two cohorts.
Prospective, open label, single blind, randomized study with inclusion of 160 patients in two equal sized cohorts (A and B). Angiographic follow-up with optical coherence tomography (OCT) is performed at 1 month (Cohort A) and 3 months (Cohort B). Randomization 1:1 to SYNERGY or BioMatrix Neoflex. The Cohorts are included consecutively, Cohort A first.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SYNERGY drug eluting stent | Experimental | Everolimus eluting bioresorbable polymer stent |
|
| Biomatrix NeoFlex drug eluting stent | Experimental | Biolimus eluting bioresorbable polymer stent |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Everolimus eluting bioresorbable polymer stent | Device |
|
| |
| Measure | Description | Time Frame |
|---|---|---|
| Coronary Stent Healing Index | Combined endpoint of vessel wall healing parameters assessed by optical coherence tomography (OCT) | 1 or 3 months |
| Uncovered stent struts | Uncovered stent struts 2%=1, 5%=2, 10%=3, 15%=4, 20%=5, 25%=6, 30%=7, 35%=8, 40%=9 | 1 or 3 months |
| Uncovered stent struts in front of SBs, on acquired or persistent malapposed struts | Uncovered stent struts in front of side branchs (SB), on acquired or persistent malapposed struts10%=1, 20%=2, 30%=3 etc to 100%=0 | 1 and 3 months |
| Persistent malapposition | Persistent malapposition: >2 adjacent struts of at least 1 mm length =1; >2 mm=2; >3 mm=3 | 1 and 3 months |
| Neointimal thickness in one frame or lumen mean diameter stenosis | Neointimal thickness in one frame or lumen mean diameter stenosis >200=1; >300=2; >400=3 or diameter stenosis >50%=4; >75%=5 | 1 and 3 months |
| Acquired malapposition | Acquired malapposition: >2 adjacent struts of at least 1 mm length =2; > 2 mm=4; > 3 mm=6 | 1 and 3 months |
| Cumulated extra stent lumen increase in matched cross sectional analysis | Cumulated extra stent lumen increase in matched cross sectional analysis (measurement mean area) |
| Measure | Description | Time Frame |
|---|---|---|
| Malapposition | Detectable separation between the vessel wall and strut in a cross section. | Baseline, 1 and 3 months |
| Coverage | Detectable tissue covering the strut |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Evald H Christiansen, MD | Aarhus University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aarhus University Hospital, Skejby | Aarhus | 8200 | Denmark | |||
| Odense University Hospital |
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D000787 | Angina Pectoris |
| D009203 | Myocardial Infarction |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Biolimus eluting bioresorbable polymer stent |
| Device |
|
|
| 1 and 3 months |
| Baseline, 1 and 3 months |
| Fracture | Discontinuity of a strut evaluated by 3D reconstruction | Baseline, 1 and 3 months |
| Neointimal thickness (NIT) | Thickness of intima from leading strut surface to lumen boarder | Baseline, 1 and 3 months |
| Lumen area | Area of lumen in cross section | Baseline, 1 and 3 months |
| Stent area | Area of stent in cross section | Baseline, 1 and 3 months |
| Area stenosis (AS) % | Minimal luminal area/reference area (interpolated) | Baseline, 1 and 3 months |
| Minimum expansion of the stent | Expressed as absolute area and percentage of the closest reference area | Baseline, 1 and 3 months |
| Late recoil | Loss in stent area from baseline to follow-up | Baseline, 1 and 3 months |
| Lumen late loss | Loss in minimal lumen area from baseline to follow-up | Baseline, 1 and 3 months |
| Extra stent lumen | Area outside stent boarder limited by lumen boarder | Baseline, 1 and 3 months |
| Evaginations | Counts and descriptive by size (volume and depth) | Baseline, 1 and 3 months |
| Thrombus on struts | In final OCT after implantation and at follow-up | Baseline, 1 and 3 months |
| Acute expansion and late recoil | In segments with; 1)calcified plaque, 2)lipid plaque, 3)area after predilatation <30% of reference area, 4)stenosed segments (>50% AS) with no dissections after predilatation | Baseline, 1 and 3 months |
| Target Lesion Failure (TLF) | Stent related combined endpoint of Target Lesion Failure (TLF) hierarchically as cardiac death, non-index procedure related AMI (defined as AMI not clearly related to another lesion than the target lesion), or Target Lesion Revascularisation (TLR) (by PCI or CABG - TLR if significant stenosis + 5mm distal/proximal) | Within 12 months |
| Cardiac death | Stent related, major adverse cardiac events (MACE), serious complication at procedure | Baseline, 12, 24, 36, 48 and 60 months |
| Non-index procedure related acute myocardial infarction (AMI) | Defined as AMI not clearly related to another lesion than the target lesion | Baseline and within 12, 24, 36, 48 and 60 months |
| Target Lesion Revascularisation (TLR) | New revascularisation of TLR by percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) (TLR if significant stenosis += 5 mm distal/proximal) | Baseline and within 12, 24, 36, 48 and 60 months |
| All-cause death | 12, 24, 36, 48 and 60 months |
| Stent thrombosis | According to ARC criteria | Baseline, 1, 12, 24, 36, 48 and 60 months |
| Device success rate | Defined as the frequency of successful implantation with residual stenosis <20% of the study stent in all the stenoses scheduled to be treated | Baseline |
| Procedural success rate | Defined as the frequency of successful implantation with residual stenosis <20% of the study stent in all the stenoses scheduled to be treated and without serious complications | Baseline |
| Odense |
| 5000 |
| Denmark |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002637 | Chest Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007238 | Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D009336 | Necrosis |